Transcranial Magnetic Stimulation (TMS) for Treatment-Resistant Depression
Repetitive transcranial magnetic stimulation (rTMS) is recommended for patients with major depressive disorder who have failed 2 or more adequate antidepressant medication trials, with evidence showing significant improvements in depressive symptoms and remission rates compared to sham treatment. 1
What is TMS?
TMS is a non-invasive neuromodulation technique that uses electromagnetic pulses to stimulate cortical neurons. When applied repetitively (rTMS), it has demonstrated antidepressant effects, receiving FDA clearance for treatment-resistant depression (TRD) in 2008. 2
Clinical Efficacy
The 2022 VA/DoD guidelines maintain their recommendation for rTMS based on aggregate evidence showing:
- Number needed to treat: 3.4 to 9 patients for response
- Number needed to treat: 5 to 7 patients for remission 1
Meta-analytic data demonstrates rTMS produces:
- Clinically meaningful decrease in depression severity (>4 points on Hamilton Depression Rating Scale compared to sham) 3
- 3.38 times higher response rates versus sham treatment 3
- 5.07 times higher remission rates versus sham treatment 3
Recent real-world data shows response rates of 52% and remission rates of 24-42% in TRD populations. 4, 5
Standard Treatment Protocol
The typical rTMS protocol involves:
- Target: Left dorsolateral prefrontal cortex
- Frequency: 10 Hz (high-frequency stimulation)
- Intensity: 120% of motor threshold
- Duration: Up to 30 treatment sessions
- Schedule: Daily sessions over 4-6 weeks 1, 4
Important Nuance: The Veteran Population Study
A critical caveat exists: One recent high-quality RCT in veterans with TRD (n=164) found no significant differences between active rTMS and sham at treatment completion or 24 weeks, despite both groups showing 39% remission rates. 1 This study population had high rates of comorbid PTSD and substance use disorder, raising the possibility that:
- Placebo effects from frequent clinical visits play a substantial role
- Comorbid conditions may reduce rTMS efficacy
- Patient expectancy significantly influences outcomes
However, the guideline workgroup determined this single study was insufficient to overturn the broader evidence base supporting rTMS efficacy. 1
Theta-Burst Stimulation (TBS)
There is insufficient evidence to recommend for or against theta-burst stimulation, a rapid-pulse variation of TMS. 1 While one study showed TBS improvement over sham at 12 weeks, differences disappeared at 24 weeks for the critical outcome of remission. Evidence quality remains very low due to small sample sizes. 1
Accelerated Protocols
Emerging evidence supports accelerated rTMS protocols (multiple sessions per day over shorter timeframes) for faster symptom improvement, though long-term durability data remains limited. 2, 4
Combining with Antidepressants
Continue antidepressants when initiating rTMS. Meta-analysis shows combining TMS with pre-specified antidepressants from the outset produces greater efficacy (Hedge's g = 1.0) than either treatment alone. 6 Do not discontinue existing antidepressants when starting rTMS treatment.
Safety Profile
rTMS demonstrates minimal and manageable adverse events with benefits outweighing harms. 1 The most common side effects include scalp discomfort and headache. Seizure risk is extremely low when proper protocols are followed.
Key Clinical Considerations
Predictors of better response:
- Younger age
- Lower degree of treatment resistance (fewer failed medication trials)
- Absence of comorbid anxiety or psychotic symptoms 7
Primary barrier to treatment: Access remains challenging as rTMS requires frequent on-site visits (typically daily for 4-6 weeks), which may be logistically difficult for many patients. 1
Patient selection: Reserve rTMS for patients who have documented failure of at least 2 adequate antidepressant trials. Screen carefully for comorbid PTSD and substance use disorders, as these may reduce treatment efficacy based on the veteran population data. 1